Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Diabetes Mellitus, Type 2 1

Interventions

relacorilant 4Resistance Training 3Pioglitazone 3Dipeptidyl-Peptidase IV Inhibitors 3Sulfonylurea Compounds 2Rosiglitazone 2Nutritional Status 2Metformin 2voglibose 1saxagliptin 1repaglinide 1pembrolizumab 1miglitol 1metahexamide 1meglitinide 1glymidine 1glisoxepide 1gliquidone 1glimepiride 1glibornuride 1empagliflozin 1Vildagliptin 1Troglitazone 1Tolbutamide 1Tolazamide 1Thiazolidinediones 1Surveys and Questionnaires 1Sodium-Glucose Transporter 2 Inhibitors 1Sitagliptin Phosphate 1Resistant Starch 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Diabetes Mellitus, Type 2 × Nateglinide × Clear all
NCT02475499 2016-03-14

Incretin-based Drugs and Pancreatic Cancer

Canadian Network for Observational Drug Effect Studies, CNODES

Completed
886,172 enrolled
Gastrointestinal

Diabetes Mellitus, Type 2, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡